CYTOKINETICS INC CYTK
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
2/9
Piotroski F — financial health
-7.91
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $88.0M | -$785.0M | — | -$534.8M | -$659.6M |
| 2024 | $18.5M | -$589.5M | — | -$399.8M | -$135.4M |
| 2023 | $7.5M | -$526.2M | — | -$415.7M | -$386.3M |
| 2022 | $94.6M | -$389.0M | — | -$310.9M | -$107.9M |
| 2021 | $70.4M | -$215.3M | — | -$191.4M | $243.9M |
| 2020 | $55.8M | -$127.3M | — | -$2.1M | $113.4M |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -7.91 (distress)
- Working capital / assets 0.502
- Retained earnings / assets -2.448
- EBIT / assets -0.43
- Equity / liabilities -0.316
Source: SEC EDGAR filings · CIK 0001061983 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.